Prometrium Cost in Alaska 2026: Cash Price, Insurance, and Compounding Options

What Is Prometrium and Why Does the Price Vary So Much in Alaska?

Prometrium is the brand-name oral capsule formulation of micronized progesterone, approved by the FDA for prevention of endometrial hyperplasia in non-hysterectomized women receiving conjugated estrogens, and for secondary amenorrhea. The FDA prescribing information specifies a 200 mg dose taken orally at bedtime for 12 consecutive days per 28-day cycle when used with estrogen therapy.

Alaska's geography shapes drug pricing in ways that residents of the lower 48 rarely encounter. Remote distribution logistics, a smaller pharmacy density, and a relatively thin payer mix all push retail prices above national averages for many medications. Yet for Prometrium specifically, the cash price at Alaskan retail pharmacies sits around $45 per month in 2026, well below the $180 manufacturer list price, because most pharmacies participate in third-party discount networks.

No FDA-approved generic micronized progesterone capsule existed as of the 2026 publication date of this article. That single fact explains why compounding remains a significant cost lever for Alaskan patients.

How the List Price vs. Cash Price Gap Works

AbbVie inherited the Prometrium brand through its acquisition of Allergan, which had acquired Solvay Pharmaceuticals. The Wholesale Acquisition Cost (WAC) sits near $180 per month for a 30-capsule supply of 200 mg capsules. Pharmacies negotiate their own acquisition costs, and discount programs like GoodRx often bring the patient-facing cash price down to the $40-$50 range at Anchorage, Fairbanks, and Juneau retail chains.

Patients in rural Alaska, including those served by smaller community pharmacies in towns like Bethel or Nome, may face prices closer to $60-$70 per month due to reduced competition and higher freight costs.

Why No Generic Exists

Micronized progesterone in an oil-based soft-gel capsule presents bioavailability and formulation challenges that have so far prevented a successful ANDA (Abbreviated New Drug Application) approval. The FDA's Orange Book lists no approved generic as of January 2026. This regulatory gap is the direct reason branded Prometrium retains pricing power and why 503A compounding fills a real clinical gap for cost-sensitive patients.

Alaska Medicaid and Prometrium: What the Coverage Rules Actually Say

Alaska Medicaid does not cover Prometrium for endometrial protection in the context of hormone replacement therapy. This is a firm exclusion as of 2026, confirmed by Alaska Division of Health Care Services preferred drug list publications.

Patients enrolled in Denali KidCare or the Alaska Comprehensive Health Insurance Association (ACHIA) plan should verify coverage individually, as supplemental Medicaid programs carry separate formularies. A direct call to the Alaska Medicaid pharmacy help line (1-800-780-9972) will confirm current tier placement before filling a prescription.

What Medicaid Will Cover

Alaska Medicaid does cover micronized progesterone in limited clinical contexts outside of standard HRT. These include:

• Threatened miscarriage protocols (coverage is case-by-case and requires prior authorization)
• Progesterone supplementation in certain ART (assisted reproductive technology) cycles when documentation is submitted by a reproductive endocrinologist

Neither of these pathways applies to menopausal women using progesterone to protect the uterine lining during estrogen therapy.

Prior Authorization Pathways

Even in covered categories, prior authorization (PA) is standard. Alaska Medicaid's PA review team requires a diagnosis code, the prescribing provider's NPI, and clinical notes documenting why brand Prometrium is medically necessary over a compounded alternative. Approval rates for HRT-related PA requests are low based on current formulary policy.

Private Insurance Coverage for Prometrium in Alaska

Private insurance plans sold on the Alaska Health Insurance Marketplace vary considerably in how they handle Prometrium. Most tier it as a Tier 2 or Tier 3 brand drug, meaning copays typically run $40-$80 per month with insurance, which can actually exceed the cash price at discount pharmacies.

Checking Your Plan Formulary

The fastest way to confirm coverage is to call the member services number on the back of your insurance card and ask:

1. Is NDC 00032-1708-01 (Prometrium 200 mg 30-capsule) on my formulary?
2. What tier is it listed under?
3. Is a step-therapy or prior authorization requirement in place?

Premera Blue Cross of Alaska, Moda Health, and BCBS Federal Employee Program (FEP) are among the larger carriers serving Alaskan residents. BCBS FEP generally covers Prometrium at the preferred brand tier with a roughly $60 copay per 30-day supply.

Step Therapy Requirements

Several Alaska commercial plans impose step therapy, requiring a documented trial of an alternative progestogen, typically medroxyprogesterone acetate (MPA), before authorizing Prometrium. If your prescriber has a clinical reason to avoid MPA (for example, a patient with depression or adverse lipid response to synthetic progestins), a step-therapy exemption letter citing the clinical rationale can often override this requirement.

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875, JAMA 1995) demonstrated that micronized progesterone produced a more favorable HDL-cholesterol profile than MPA when combined with estrogen, a finding that prescribers frequently cite when arguing for Prometrium over MPA on clinical grounds. PEPI trial, JAMA 1995

Compounded Micronized Progesterone in Alaska: Legality and Cost

Compounded micronized progesterone is legal in Alaska when prepared by a state-licensed pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. 503A pharmacies compound for individual patients based on a valid prescription from a licensed practitioner.

The average cost for compounded micronized progesterone through an Alaskan or lower-48 mail-order 503A pharmacy is approximately $25 per month, roughly 44% less than retail cash price for branded Prometrium, and 86% less than list price.

What 503A Means for Patients

A 503A pharmacy must meet state board of pharmacy licensure requirements and comply with USP <795> and USP <797> standards for non-sterile and sterile preparations, respectively. Oral micronized progesterone capsules are non-sterile, so USP <795> governs their preparation. Alaska Board of Pharmacy licensure records are publicly searchable at the Alaska Division of Corporations, Business, and Professional Licensing website.

503A compounding differs critically from 503B (outsourcing facility) compounding. 503B facilities produce large batches without individual patient prescriptions and face more rigorous FDA oversight. For individual patients, 503A is the relevant pathway.

Bioavailability Considerations with Compounded Formulations

Prometrium capsules use a peanut oil-based vehicle to enhance the oral bioavailability of micronized progesterone. Compounded versions may use alternative vehicles such as olive oil or MCT (medium-chain triglyceride) oil. Studies have shown that the lipid vehicle significantly affects progesterone absorption. A 2019 pharmacokinetic analysis published in Menopause (the journal of the Menopause Society) found that oil-based oral vehicles produce substantially higher serum progesterone levels than aqueous or powder-filled capsules. Stanczyk FZ et al., Menopause 2019

Patients switching from brand Prometrium to a compounded alternative should have a follow-up serum progesterone level drawn 4-6 weeks after the switch to confirm therapeutic exposure. A mid-luteal serum progesterone level of at least 5 ng/mL is generally considered evidence of adequate absorption for endometrial protection, though the specific threshold your provider targets may vary.

Which Compounding Pharmacies Serve Alaska?

Alaska residents can legally receive compounded prescriptions by mail from 503A pharmacies licensed in the sending state, provided the Alaska Board of Pharmacy recognizes the sending state's license (which it does for all 50 states under current reciprocity policy). Women in remote Alaskan communities who cannot access a local compounding pharmacy can work with their telehealth prescriber to route the prescription to a vetted lower-48 503A pharmacy that ships to Alaska.

Telehealth Prescribing of Prometrium in Alaska

Prometrium may be prescribed via telehealth in Alaska. The state does not impose a mandatory in-person examination requirement for initiating hormone therapy, provided the prescribing clinician conducts a clinically sufficient evaluation through synchronous audio-video technology.

Alaska adopted interstate telehealth prescribing provisions aligned with the Ryan Haight Act amendments. A prescriber licensed in Alaska, or licensed in another state and holding an Alaska telehealth registration, may issue a Prometrium prescription after a real-time clinical encounter.

What a Telehealth HRT Evaluation Includes

A compliant telehealth evaluation for Prometrium typically covers:

• Menstrual and menopausal history
• Review of uterine status (hysterectomy history)
• Symptom severity scoring (commonly using the Menopause Rating Scale or Greene Climacteric Scale)
• Contraindication screening, including personal or family history of breast cancer, thromboembolic disease, and active liver disease
• Blood pressure measurement (patient-reported or recent lab values)
• Baseline labs ordered remotely if not recently completed

The HealthRX clinical team uses a structured intake protocol that flags patients with a uterus who are prescribed estrogen therapy without concurrent progesterone, triggering an automatic prescriber alert before any estrogen prescription is finalized. This protocol reflects the American College of Obstetricians and Gynecologists (ACOG) guidance that unopposed estrogen in women with a uterus carries an unacceptable risk of endometrial hyperplasia and carcinoma. ACOG Practice Bulletin No. 141

The AbbVie/Solvay Savings Card: How It Works in Alaska

AbbVie operates a Prometrium patient savings program (formerly under the Solvay brand) that may reduce out-of-pocket cost for commercially insured patients who are not covered by a government payer including Medicare, Medicaid, or TRICARE. Alaska residents who qualify pay as little as $25-$35 per fill under the program, though benefit caps and eligibility criteria apply.

Eligibility Rules

To use the savings card:

• Patient must have a valid Prometrium prescription from a licensed U.S. Prescriber
• Patient must be covered by commercial insurance (the program does not apply to cash-pay patients without insurance, though some discount stacking is possible)
• Government insurance beneficiaries (Medicare Part D, Alaska Medicaid, TRICARE) are explicitly excluded
• Annual benefit caps vary; confirm the current cap on the AbbVie program website before relying on savings projections for a full year

Using the Card at Alaskan Pharmacies

The savings card functions like a secondary insurance at the point of sale. Pharmacies in the lower 48 process it routinely; some smaller Alaskan community pharmacies may need the technician to manually enter the BIN and PCN numbers printed on the card. Calling ahead to confirm the pharmacy can process the card before making the trip is worth the two-minute phone call.

Cheapest Strategies for Getting Prometrium in Alaska: A Ranked Comparison

The table below ranks cost options from lowest to highest average monthly out-of-pocket for a 200 mg daily Prometrium regimen in Alaska in 2026.

| Option | Estimated Monthly Cost | Notes | |---|---|---| | Compounded micronized progesterone (503A, mail) | ~$25 | Requires prescriber willing to write for compounded product | | GoodRx or similar discount at Anchorage retail pharmacy | ~$38-$50 | No insurance needed; price varies by pharmacy | | AbbVie savings card (commercially insured) | ~$25-$35 | Caps apply; government payers ineligible | | Commercial insurance (Tier 2 brand copay) | ~$40-$80 | Step therapy may be required | | Cash pay at rural Alaska pharmacy | ~$60-$70 | Higher due to freight and lower competition | | Alaska Medicaid | Not covered | No pathway for standard HRT indication | | Medicare Part D | Varies by plan; often Tier 3 or non-formulary | Compare plans during open enrollment |

The single most cost-effective strategy for most Alaskan patients without commercial insurance is a compounded micronized progesterone prescription from a telehealth provider sent to a vetted mail-order 503A pharmacy.

Clinical Evidence Supporting Micronized Progesterone Over Synthetic Progestins

The choice between Prometrium and synthetic progestins like medroxyprogesterone acetate is not merely a cost question. A body of clinical evidence suggests micronized progesterone carries a more favorable risk and tolerability profile.

The PEPI Trial (1995)

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial enrolled 875 postmenopausal women aged 45-64 and followed them for three years. Women receiving conjugated equine estrogen plus micronized progesterone maintained HDL-cholesterol gains comparable to estrogen-alone therapy, while those receiving CEE plus MPA saw HDL gains partially attenuated. The PEPI investigators concluded that micronized progesterone was the progestogen of choice when HDL preservation was a treatment goal. PEPI Investigators, JAMA 1995, PMID 7837245

The E3N Cohort Study

The French E3N prospective cohort study (N=80,377 postmenopausal women, followed 1990-2002) found that women using estrogen combined with micronized progesterone had no statistically significant increase in breast cancer risk compared to non-users (relative risk 1.00, 95% CI 0.83-1.22). Women using estrogen combined with synthetic progestins faced a relative risk of 1.69 (95% CI 1.50-1.91). Fournier A et al., Breast Cancer Res Treat 2008

Endometrial Protection Evidence

The FDA approved Prometrium specifically on the basis of its endometrial protection when combined with conjugated estrogens, citing data showing that 200 mg daily for 12 days per cycle reduced the rate of endometrial hyperplasia to less than 1% over 12 months, compared to roughly 20% in the estrogen-alone arm. This endpoint is what insurers and prescribers reference when defining clinical necessity.

Monitoring Requirements After Starting Prometrium

Starting Prometrium is not a set-and-forget prescription. The Menopause Society (formerly NAMS) recommends that women on combined HRT have an annual clinical review addressing symptom control, side-effect profile, and cardiovascular risk factors. "The 2023 Menopause Society Position Statement on Hormone Therapy," Menopause 2023

Labs and Imaging

Routine serum progesterone monitoring is not required during Prometrium therapy for endometrial protection, unlike with vaginal progesterone or certain compounded formulations where absorption is less predictable. However, any new episode of unscheduled uterine bleeding in a patient on combined HRT warrants prompt evaluation, typically with a transvaginal ultrasound to assess endometrial stripe thickness and, if the stripe exceeds 4 mm, an endometrial biopsy.

Side-Effect Profile

Micronized progesterone's side-effect profile is dominated by its sedating properties, which derive from its conversion to allopregnanolone, a positive GABA-A receptor modulator. Taken at bedtime as directed, this sedation often benefits women with insomnia during perimenopause. Daytime sedation, dizziness, and bloating affect a minority of users. Peanut allergy is a firm contraindication to Prometrium capsules given the peanut oil vehicle; compounded formulations using alternative oils are the appropriate substitute in that setting.